Investigation into Alleged Securities Fraud by Viatris Inc.
New York, NY – April 2, 2025
The Rosen Law Firm, a leading global investor rights law firm, is actively investigating potential securities claims on behalf of shareholders of Viatris Inc. (NASDAQ: VTRS) following allegations that the company may have disseminated materially misleading business information to the public.
Background
Viatris is a global healthcare company focused on providing branded and generic medicines. The company was formed through the merger of Mylan N.V. and Upjohn, a division of Pfizer Inc., in August 2020. Viatris’s product portfolio includes a wide range of therapeutic areas, including cardiovascular disease, neuroscience, oncology, and more.
Allegations of Securities Fraud
The Rosen Law Firm’s investigation comes in response to a report published by a short-seller research firm alleging accounting irregularities and potential fraud at Viatris. The report, which was released in late March 2025, claimed that Viatris had inflated its revenue and earnings by as much as $1.5 billion through aggressive pricing tactics and other questionable accounting practices.
Potential Impact on Shareholders
If the allegations are proven true, Viatris shareholders may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is urging investors who purchased Viatris securities between certain dates to contact the firm for more information.
Global Implications
The potential securities fraud allegations against Viatris are not only significant for the company and its shareholders but also carry wider implications for the global pharmaceutical industry. The allegations could lead to increased scrutiny of accounting practices and business models within the sector, potentially impacting investor confidence and market dynamics.
Additional Sources
- Bloomberg: Viatris Faces Probe Over Alleged Accounting Irregularities
- Reuters: Viatris shares plunge on short-seller report of accounting irregularities
- Seeking Alpha: Viatris: A Short Seller’s Report
According to these sources, Viatris’s stock price experienced a significant decline following the release of the short-seller report, with shares dropping by more than 20% in intraday trading.
Conclusion
The Rosen Law Firm’s investigation into potential securities claims against Viatris is a reminder of the importance of accurate and transparent business information in the financial markets. As the allegations continue to unfold, investors should stay informed and consult with their financial advisors to assess the potential impact on their portfolios.
For more information, interested parties are encouraged to contact The Rosen Law Firm at 212-614-5400 or submit the online form available on their website.
